Kazia Therapeutics Limited
KZIA · NASDAQ
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | – | $12,155 | $9,369 | $15,837 |
| - Cash | $4,345 | $3,064 | $1,657 | $3,563 |
| + Debt | $0 | $141 | $634 | $359 |
| Enterprise Value | – | $9,232 | $8,346 | $12,634 |
| Revenue | – | $22 | $2,481 | $0 |
| % Growth | – | -99.1% | 49,619,800% | – |
| Gross Profit | – | $22 | $2,481 | $0 |
| % Margin | – | 100% | 100% | 100% |
| EBITDA | – | -$8,434 | -$18,644 | -$7,949 |
| % Margin | – | -37,836.1% | -751.5% | -158,973,960% |
| Net Income | – | -$10,454 | -$17,954 | -$8,824 |
| % Margin | – | -46,899.1% | -723.7% | -176,470,260% |
| EPS Diluted | – | -6.15 | -31.2 | -18.4 |
| % Growth | – | 80.3% | -69.6% | – |
| Operating Cash Flow | – | -$4,210 | -$3,246 | -$6,335 |
| Capital Expenditures | – | $0 | $0 | $0 |
| Free Cash Flow | – | -$4,210 | -$3,246 | -$6,335 |